Advertisement
Screener

RIGEL PHARMACEUTICALS, INC. (RIGL) EBITDA

RIGEL PHARMACEUTICALS, INC. (RIGL) EBITDA

  • 2026-06-30: Basis Reported; EBITDA $24.42M*; Operating income $23.57M; Depreciation and amortization $848.00K*.
  • 2026-03-31: Basis Reported; EBITDA $12.48M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA $23.77M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA $29.02M*; Operating income $28.42M; Depreciation and amortization $603.00K*.

Complete source-backed ebitda history.

Available history
2009-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported$24.42M*$23.57M$848.00K*$78.70M31.03%*(m)$30.65M*$8.53M$13.96M$32.64M$6.29M
2026-03-31Reported$12.48M(m)(m)(m)21.22%(m)$2.73M$4.61M$11.68M$30.65M$3.00M
2025-12-31Reported$23.77M(m)(m)(m)34.05%(m)(m)(m)(m)(m)(m)
2025-09-30Reported$29.02M*$28.42M$603.00K*$69.46M41.78%*(m)$24.03M*$4.75M(m)$28.94M-$280.00K
2025-06-30Reported$61.71M*$61.10M$607.00K*$101.69M60.69%*(m)$30.54M*$4.50M$6.82M$29.26M$369.00K
2025-03-31Reported$13.38M(m)(m)(m)25.08%(m)-$893.00K$4.41M$8.44M$27.71M$65.00K
2024-12-31Reported$17.26M(m)(m)(m)29.97%(m)(m)(m)(m)(m)(m)
2024-09-30Reported$14.67M*$14.06M$611.00K*$55.31M26.52%*(m)$21.68M*$8.03M(m)$27.04M$0.00
2024-06-30Reported$1.06M*$447.00K$613.00K*$36.84M2.88%*(m)$302.00K*$2.81M(m)$28.05M$0.00
2024-03-31Reported-$6.57M(m)(m)(m)-22.23%(m)-$5.01M$2.02M(m)$28.45M$0.00
2023-12-31Reported$2.26M(m)(m)(m)6.31%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$4.17M*-$4.46M$292.00K*$28.13M-14.83%*(m)-$1.36M*$1.27M(m)$24.86M(m)
2023-06-30Reported-$4.97M*-$5.27M$296.00K*$26.89M-18.49%*(m)$5.93M*$1.07M(m)$26.31M(m)
2023-03-31Reported-$12.37M(m)(m)(m)-47.44%(m)-$4.07M$977.00K(m)$27.73M(m)
2022-12-31Reported$2.36M(m)(m)(m)4.61%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$18.16M*-$18.40M$240.00K*$22.41M-81.05%*$189.00K*-$13.30M*$250.00K(m)$25.90M$0.00
2022-06-30Reported-$12.73M*-$12.96M$237.00K*$29.82M-42.68%*-$36.00K*-$12.91M*$1.04M(m)$26.98M$0.00
2022-03-31Reported-$26.02M(m)(m)(m)-155.51%$224.00K-$25.64M$121.00K(m)$27.40M$0.00
2021-12-31Reported-$21.01M(m)(m)(m)-102.96%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$19.52M*-$19.79M$261.00K*$21.54M-90.63%*$170.00K*-$10.30M*$151.00K(m)$22.88M-$136.00K
2021-06-30Reported-$12.79M*-$13.05M$258.00K*$26.27M-48.69%*$407.00K*$55.22M*$129.00K(m)$22.38M-$970.00K
2021-03-31Reported$41.99M(m)(m)(m)51.83%$71.00K-$19.95M$316.00K(m)$22.12M$1.77M
2020-12-31Reported-$18.62M(m)(m)(m)-100.93%(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$13.62M*-$13.78M$165.00K*$18.39M-74.04%*$195.00K*-$19.48M*$140.00K(m)$17.43M$0.00
2020-06-30Reported-$17.23M*-$17.39M$164.00K*$16.02M-107.53%*-$44.00K*-$14.04M*$279.00K(m)$18.92M$0.00
2020-03-31Reported$21.2M(m)(m)(m)38.02%$607.00K-$3.09M$155.00K(m)$18.43M$0.00
2019-12-31Reported-$17.16M(m)(m)(m)-111.41%(m)(m)(m)(m)(m)(m)
2019-09-30Reported-$11.87M*-$12.04M$166.00K*$20.86M-56.92%*$352.00K*-$14.64M*$310.00K(m)$18.12M(m)
2019-06-30Reported-$21.17M*-$21.34M$173.00K*$10.41M-203.38%*$115.00K*-$16.65M*$311.00K(m)$18.21M(m)
2019-03-31Reported-$18.21M(m)(m)(m)-144.28%$377.00K-$569.00K$107.00K(m)$19.95M(m)
2018-12-31Reported$2.7M(m)(m)(m)7.12%(m)(m)(m)(m)(m)(m)
2018-09-30Reported-$24.21M*-$24.37M$159.00K*$4.87M-497.66%*$156.00K*-$20.08M*$69.00K(m)$18.07M(m)
2018-06-30Reported-$25.95M*-$26.11M$159.00K*$1.79M-1452.27%*$684.00K*-$26.99M*$30.00K(m)$17.07M(m)
2018-03-31Reported-$24.62M(m)(m)(m)(m)$197.00K-$23.39M(m)(m)$13.49M(m)
2017-12-31Reported-$26.1M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2017-09-30Reported-$17.74M*-$17.86M$112.00K*$900.00K-1971.44%*$56.00K*-$17.61M*(m)(m)(m)(m)
2017-06-30Reported-$19.23M*-$19.34M$114.00K*(m)(m)$14.00K*-$19.47M*(m)(m)(m)(m)
2017-03-31Reported-$16.08M(m)(m)(m)(m)$41.00K-$20.76M(m)(m)(m)(m)
2016-12-31Reported-$15.64M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-09-30Reported-$22.52M*-$22.74M$214.00K*(m)(m)$252.00K*-$22.57M*(m)(m)(m)(m)
2016-06-30Reported-$13.39M*-$13.65M$260.00K*(m)(m)$225.00K*(m)(m)(m)(m)(m)
2016-03-31Reported-$17.24M(m)(m)(m)(m)$321.00K(m)(m)(m)(m)(m)
2015-12-31Reported-$12.41M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-09-30Reported-$6.49M*-$6.78M$287.00K*(m)(m)$307.00K*(m)(m)(m)(m)(m)
2015-06-30Reported-$13.60M*-$13.97M$379.00K*(m)(m)$73.00K*(m)(m)(m)(m)(m)
2015-03-31Reported-$17.81M(m)(m)(m)(m)$32.00K(m)(m)(m)(m)(m)
2014-12-31Reported-$21.86M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-09-30Reported-$20.47M*-$21.04M$574.00K*(m)(m)-$40.00K*(m)(m)(m)(m)(m)
2014-06-30Reported-$24.83M*-$25.46M$623.00K*(m)(m)$75.00K*(m)(m)(m)(m)(m)
2014-03-31Reported-$21.73M(m)(m)(m)(m)$178.00K(m)(m)(m)(m)(m)
2013-12-31Reported-$16.29M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-09-30Reported-$23.29M*-$23.93M$644.00K*(m)(m)$128.00K*(m)(m)(m)(m)(m)
2013-06-30Reported-$22.26M*-$22.89M$628.00K*(m)(m)$249.00K*(m)(m)(m)(m)(m)
2013-03-31Reported-$25.04M(m)(m)(m)(m)$676.00K(m)(m)(m)(m)(m)
2012-12-31Reported-$24.98M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-09-30Reported-$24.93M*-$25.57M$635.00K*(m)(m)$384.00K*(m)(m)(m)(m)(m)
2012-06-30Reported-$24.27M*-$24.88M$610.00K*(m)(m)$818.00K*(m)(m)(m)(m)(m)
2012-03-31Reported-$22.76M(m)(m)(m)(m)$1.57M(m)(m)(m)(m)(m)
2011-12-31Reported-$25.38M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-09-30Reported-$17.54M*-$18.04M$506.00K*(m)(m)$561.00K*(m)(m)(m)(m)(m)
2011-06-30Reported-$21.08M*-$21.56M$476.00K*(m)(m)$697.00K*(m)(m)$17.11M(m)(m)
2011-03-31Reported-$20.41M(m)(m)(m)(m)$860.00K(m)(m)(m)(m)(m)
2010-12-31Reported-$19.28M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2010-09-30Reported$50.69M*$50.36M$327.00K*(m)(m)$897.00K*(m)(m)(m)(m)(m)
2010-06-30Reported(m)$26.98M(m)(m)(m)(m)(m)(m)$16.82M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported$127.88M(m)(m)(m)43.46%(m)$75.66M$19.62M$33.30M$115.90M-$245.20M
2024-12-31Reported$26.42M(m)(m)(m)14.74%(m)$31.47M$18.65M$23.38M$113.06M$881.00K
2023-12-31Reported-$19.25M(m)(m)(m)-16.47%(m)-$5.74M$7.11M$24.52M$105.74M$0.00
2022-12-31Reported-$54.55M(m)(m)(m)-45.37%$450.00K-$73.76M$1.75M(m)$112.45M(m)
2021-12-31Reported-$11.33M(m)(m)(m)-7.59%$627.00K$5.88M$1.08M(m)$91.89M$605.00K
2020-12-31Reported-$28.27M(m)(m)(m)-26.02%$1.26M-$52.19M$895.00K(m)$76.60M(m)
2019-12-31Reported-$68.41M(m)(m)(m)-115.38%$1.46M-$41.51M$906.00K(m)$74.59M(m)
2018-12-31Reported-$72.09M(m)(m)(m)-161.96%$1.11M-$58.83M$287.00K(m)$70.00M$0.00
2017-12-31Reported-$79.15M(m)(m)(m)-1765.19%$164.00K-$77.56M(m)(m)$37.83M$0.00
2016-12-31Reported-$68.8M(m)(m)(m)-337.54%$804.00K-$75.89M(m)(m)$20.91M$0.00
2015-12-31Reported-$50.3M(m)(m)(m)(m)$546.00K-$23.41M(m)(m)(m)$0.00
2014-12-31Reported-$88.89M(m)(m)(m)(m)$413.00K(m)(m)(m)(m)$0.00
2013-12-31Reported-$86.88M(m)(m)(m)(m)$1.22M(m)(m)(m)(m)$0.00
2012-12-31Reported-$96.94M(m)(m)(m)(m)$3.38M(m)(m)(m)(m)(m)
2011-12-31Reported-$84.41M(m)(m)(m)(m)$2.30M(m)(m)(m)(m)(m)
2010-12-31Reported$36.63M(m)(m)(m)(m)$3.56M(m)(m)(m)(m)(m)
2009-12-31Reported-$110.63M(m)(m)(m)(m)$141.00K(m)(m)(m)(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
Apnimed, Inc. (APMD)United States$0.899B
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Cryoport, Inc. (CYRX)United States$0.881B-21.29
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Arbutus Biopharma Corp (ABUS)$0.965B6.19